All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
In February 2018, the AGP reported data as of cut-off date of June 2016 from a dual-stage, non-randomized phase Ib study (NCT02203773), which is assessing the safety and efficacy of venetoclax (VEN), a BCL2 inhibitor, in combination with decitabine (DEC) or azacitidine (AZA) in previously untreated older acute myeloid leukemia (AML) patients who are ineligible for standard induction therapy. Preliminary findings of this study demonstrated that VEN plus AZA or DEC was “well tolerated” in newly diagnosed patients with AML who are unfit for standard chemotherapy with promising preliminary efficacy and low early mortality rate.1
The updated data from this phase Ib study was presented by Courtney DiNardo at the 2018 American Society of Oncology (ASCO) Annual Meeting. Overall, 145 patients (median age = 74 years, range: 65–86) were enrolled and administered either VEN at a dose of 400 mg (n = 60), 800 mg (n = 74) or 1200 mg (n = 11) co-administered daily with 20 mg/m2 of DEC on days 1–5 or 75 mg/m2 of AZA on days 1–7, each 28-day cycle.2
The speaker concluded by stating that the “preliminary data suggest that 400 mg of VEN has the optimal benefit-risk profile in combination with DEC or AZA, which demonstrated a tolerable safety profile with deep responses and durable outcomes in elderly patients with AML”. Courtney DiNardo discusses this study in an interview with the AML Global Portal.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox